<!DOCTYPE html>
<html lang="en">
  <head>
	<meta charset="UTF-8" />
	<meta name="viewport" content="width=device-width, initial-scale=1.0"/>
	<title>Olmezest- Indication, Dosage & Positioning</title>
<style>
    body {
      margin: 0;
      padding: 16px;
      font-family: Arial, sans-serif;
      line-height: 1.6;
      background-color: #f9f9f9;
      color: #333;
    }
    h1 {
      background-color: #0D9A9F;
      color: white;
      padding: 10px;
      text-align: center;
      border-radius: 8px;
      margin-bottom: 20px;
    }
    h2 {
      color: #0D9A9F;
    }
</style>
  </head>
  <body>

	<h1>Olmezest</h1>

	<h2>Therapeutic Class:</h2>
	<p>Anti-hypertensive</p>

	<h2>Indication:</h2>
	<p>Olmezest is indicated for the treatment of hypertension. Olmezest AM & Olmezest H20 is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.</p>

	<h2>Dosage and Administration:</h2>
	<p>Dosage must be individualized. Olmesartan can be taken with or without food. The recommended starting dose of Olmesartan is 20 mg once daily. If additional blood pressure reduction is required, Olmesartan dose may be increased to a maximum of 40 mg daily.</p>

	<h2>Positioning (SKU wise):</h2>
	<p><strong>Olmezest</strong>: For double digit BP reduction & Vascular protection (The only ARB provides double digit BP reduction both in SBP & DBP)</p>
	<p><strong>Olmezest AM</strong>: Achieve goal BP &lt;130/80 mm (hg) even in co-morbid conditions (Olmesartan plus amlodipine provides greater % of goal BP achievement in patients having Diabetes & Obesity)</p>
	<p><strong>Olmezest H2O</strong>: In stage I & II hypertension, patients uncontrolled on monotherapy (Approved by USFDA)</p>

  </body>
</html>
